Literature DB >> 24777746

B cell-mediated pathogenesis of ANCA-mediated vasculitis.

J Charles Jennette1, Ronald J Falk.   

Abstract

B cells and their progeny that produce and release anti-neutrophil cytoplasmic autoantibodies (ANCA) are the primary cause for an aggressive form of necrotizing small vessel vasculitis. Cytoplasmic ANCA antigens are released at the surface and in the microenvironment of cytokine-primed neutrophils. Binding of ANCA to ANCA antigens activates neutrophils by both Fc receptor engagement and direct Fab'2 binding to antigen on the cell surface. ANCA-activated neutrophils release factors that induce alternative complement pathway activation, which establishes a potent inflammatory amplification loop that causes severe necrotizing vascular inflammation. The origin of the ANCA autoimmune response is unknown but appears to involve genetically determined HLA specificities that allow the autoimmune response to develop. One putative immunogenic mechanism begins with an immune response to a peptide that is complementary to the autoantigen and evolves through an anti-idiotypic network to produce autoantibodies to the autoantigen. Another putative immunogenic mechanism begins with an immune response to a microbe-derived molecular mimic of the autoantigen resulting in antibodies that cross-react with the autoantigen. Release of neutrophil extracellular traps, apoptosis, and increased granule protein expression of ANCA antigens may facilitate the initiation of an ANCA autoimmune response, augment established pathogenic ANCA production, or both. The ANCA B cell autoimmune response is facilitated by quantitatively and qualitatively impaired T cell and B cell suppression and by release from activated neutrophils of B cell-activating factors that enhance B cell proliferation and retard B cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777746      PMCID: PMC4084547          DOI: 10.1007/s00281-014-0431-y

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  73 in total

Review 1.  Antineutrophil cytoplasmic autoantibody-associated vasculitis in Chinese patients.

Authors:  Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

2.  Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

Authors:  D J Davies; J E Moran; J F Niall; G B Ryan
Journal:  Br Med J (Clin Res Ed)       Date:  1982 Aug 28-Sep 4

3.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

4.  Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Authors:  Aleeza J Roth; Joshua D Ooi; Jacob J Hess; Mirjan M van Timmeren; Elisabeth A Berg; Caroline E Poulton; JulieAnne McGregor; Madelyn Burkart; Susan L Hogan; Yichun Hu; Witold Winnik; Patrick H Nachman; Coen A Stegeman; John Niles; Peter Heeringa; A Richard Kitching; Stephen Holdsworth; J Charles Jennette; Gloria A Preston; Ronald J Falk
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

Review 5.  Advances in therapy for ANCA-associated vasculitis.

Authors:  Duvuru Geetha; Philip Seo
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

6.  Involvement of protein kinase C in C5a-primed neutrophils for ANCA-mediated activation.

Authors:  Jian Hao; Min Chen; Ming-Hui Zhao
Journal:  Mol Immunol       Date:  2012-11-28       Impact factor: 4.407

7.  Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Shen-Ju Gou; Jun Yuan; Min Chen; Feng Yu; Ming-Hui Zhao
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

8.  Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population.

Authors:  Meghan E Free; Donna O'Dell Bunch; Julie Anne McGregor; Britta E Jones; Elisabeth A Berg; Susan L Hogan; Yichun Hu; Gloria A Preston; J Charles Jennette; Ronald J Falk; Maureen A Su
Journal:  Arthritis Rheum       Date:  2013-07

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

Review 10.  Epidemiology and clinical features of systemic vasculitis.

Authors:  David G I Scott; Richard A Watts
Journal:  Clin Exp Nephrol       Date:  2013-07-11       Impact factor: 2.617

View more
  14 in total

Review 1.  Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.

Authors:  Damien Noone; Diane Hebert; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-09-05       Impact factor: 3.714

Review 2.  Unintended Immunological Consequences of Biologic Therapy.

Authors:  Sarah E Henrickson; Melanie A Ruffner; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 3.  Pathogenic and protective roles of B cells and antibodies in patients with chronic rhinosinusitis.

Authors:  Bruce K Tan; Anju T Peters; Robert P Schleimer; Kathryn E Hulse
Journal:  J Allergy Clin Immunol       Date:  2018-05       Impact factor: 10.793

4.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

5.  Urinary cell mRNA profiling distinguishes disease activity in antineutrophil cytoplasmic antibody-associated glomerulonephritis.

Authors:  Lillian Xu; Sam Kant; Faten Aqeel; Brendan Antiochos; Carol Li; Catherine Snopkowski; Philip Seo; Eric Jonas Gapud; Thangamani Muthukumar; Duvuru Geetha
Journal:  J Nephrol       Date:  2022-09-09       Impact factor: 4.393

6.  What is myeloperoxidase doing in ANCA-associated glomerulonephritis?

Authors:  William G Couser; Richard J Johnson
Journal:  Kidney Int       Date:  2015-11       Impact factor: 10.612

Review 7.  Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.

Authors:  Yang Zheng; Yinxi Zhang; Mengting Cai; Nanxi Lai; Zhong Chen; Meiping Ding
Journal:  Front Neurol       Date:  2019-01-10       Impact factor: 4.003

8.  A Lower Proportion of Regulatory B Cells in Patients with Henoch-Schoenlein Purpura Nephritis.

Authors:  Xintong Hu; Jiandong Tai; Zhihui Qu; Songchen Zhao; Li Zhang; Man Li; Xiguang Sun; Yanfang Jiang
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

Review 9.  Recent advances in understanding and treating vasculitis.

Authors:  Matthew J Koster; Kenneth J Warrington
Journal:  F1000Res       Date:  2016-06-20

Review 10.  Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis.

Authors:  Maria Prendecki; Charles D Pusey
Journal:  F1000Res       Date:  2018-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.